vTv Therapeutics Inc
VTVT
Company Profile
Business description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Contact
3980 Premier Drive
Suite 310
High PointNC27265
USAT: +1 336 841-0300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.70 | 32.60 | 0.37% |
| CAC 40 | 8,150.64 | 64.59 | 0.80% |
| DAX 40 | 24,199.50 | 238.91 | 1.00% |
| Dow JONES (US) | 47,941.95 | 55.98 | 0.12% |
| FTSE 100 | 9,837.77 | 63.45 | 0.65% |
| HKSE | 25,498.13 | 29.35 | 0.12% |
| NASDAQ | 22,978.74 | 285.42 | 1.26% |
| Nikkei 225 | 49,001.50 | 510.78 | -1.03% |
| NZX 50 Index | 13,256.77 | 39.14 | -0.29% |
| S&P 500 | 6,769.91 | 48.48 | 0.72% |
| S&P/ASX 200 | 8,588.20 | 31.70 | 0.37% |
| SSE Composite Index | 3,876.37 | 6.09 | 0.16% |